PriceTargets.com logo

Rapport Therapeutics - RAPP Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $58.83
  • Forecasted Upside: 52.69%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$38.53 As of 06/17/2026 01:22 PM ET
▲ +0.041 (0.11%)

This chart shows the closing price for RAPP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rapport Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RAPP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RAPP

Analyst Price Target is $58.83
▲ +52.69% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Rapport Therapeutics in the last 3 months. The average price target is $58.83, with a high forecast of $80.00 and a low forecast of $40.00. The average price target represents a 52.69% upside from the last price of $38.53.

This chart shows the closing price for RAPP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 investment analysts is to moderate buy stock in Rapport Therapeutics. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/18/2026
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/2/2026CitigroupReiterated RatingMarket Outperform ➝ Market Outperform
5/21/2026BTIG ResearchBoost TargetBuy ➝ Buy$53.00 ➝ $65.00
5/18/2026Truist FinancialInitiated CoverageBuy ➝ Buy$44.00 ➝ $56.00
5/8/2026BTIG ResearchReiterated RatingBuy ➝ Buy$53.00
4/22/2026BTIG ResearchReiterated RatingBuy ➝ Buy$53.00
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/10/2026Raymond James FinancialInitiated CoverageStrong-Buy$66.00
4/9/2026Raymond James FinancialInitiated CoverageStrong-Buy
3/25/2026Truist FinancialUpgradeStrong-Buy
3/11/2026Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$43.00 ➝ $46.00
3/10/2026CitigroupReiterated RatingMarket Outperform ➝ Market Outperform
3/9/2026BTIG ResearchBoost TargetBuy ➝ Buy$47.00
3/9/2026TD CowenReiterated RatingBuy ➝ Buy
2/2/2026Wells Fargo & CompanyInitiated CoverageOverweight$43.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/8/2026CitigroupReiterated RatingMarket Outperform ➝ Market Outperform
12/19/2025Wells Fargo & CompanySet Target$51.00
12/19/2025The Goldman Sachs GroupReiterated RatingBuy ➝ Buy
12/9/2025HC WainwrightBoost TargetBuy ➝ Buy$34.00 ➝ $40.00
12/8/2025BTIG ResearchReiterated RatingBuy ➝ Buy$47.00
11/19/2025BTIG ResearchInitiated CoverageBuy$47.00
11/18/2025BTIG ResearchUpgradeStrong-Buy
11/7/2025Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$77.00 ➝ $80.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/16/2025Truist FinancialInitiated CoverageBuy$44.00
9/12/2025The Goldman Sachs GroupUpgradeStrong-Buy
9/8/2025HC WainwrightBoost TargetBuy ➝ Buy$31.00 ➝ $34.00
8/6/2025HC WainwrightInitiated CoverageBuy$31.00
7/8/2025Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$28.00
4/8/2025Citizens JmpInitiated CoverageMarket Outperform$28.00
7/2/2024TD CowenInitiated CoverageBuy
7/2/2024Jefferies Financial GroupInitiated CoverageBuy$35.00
7/2/2024Stifel NicolausInitiated CoverageBuy$35.00
(Data available from 6/17/2021 forward)

News Sentiment Rating

0.80 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026

Current Sentiment

  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Rapport Therapeutics logo
Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.
Read More

Today's Range

Now: $38.53
Low: $37.64
High: $39.01

50 Day Range

MA: $36.59
Low: $32.38
High: $39.93

52 Week Range

Now: $38.53
Low: $10.51
High: $42.27

Volume

78,071 shs

Average Volume

331,814 shs

Market Capitalization

$1.84 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Frequently Asked Questions

What sell-side analysts currently cover shares of Rapport Therapeutics?

The following Wall Street research analysts have issued reports on Rapport Therapeutics in the last twelve months: BTIG Research, Citigroup Inc., Citizens Jmp, HC Wainwright, Raymond James Financial, Inc., TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Corporation, Wall Street Zen, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for RAPP.

What is the current price target for Rapport Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Rapport Therapeutics in the last year. Their average twelve-month price target is $58.83, suggesting a possible upside of 52.9%. Citizens Jmp has the highest price target set, predicting RAPP will reach $80.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $40.00 for Rapport Therapeutics in the next year.
View the latest price targets for RAPP.

What is the current consensus analyst rating for Rapport Therapeutics?

Rapport Therapeutics currently has 1 sell rating, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RAPP.

What other companies compete with Rapport Therapeutics?

Other companies that are similar to Rapport Therapeutics include Spyre Therapeutics, Kymera Therapeutics, Praxis Precision Medicines, Vaxcyte and Protagonist Therapeutics. Learn More about companies similar to Rapport Therapeutics.

How do I contact Rapport Therapeutics' investor relations team?

The company's listed phone number is (857) 321-8020 and its investor relations email address is [email protected]. The official website for Rapport Therapeutics is www.rapportrx.com. Learn More about contacing Rapport Therapeutics investor relations.